Carbohydrates
We are a leader in the development and production of glucose poly- and oligosaccharides and their derivatives for pharmaceutical, high-tech and medical use.
Our ambition is to become the world’s preferred partner in the management of iron deficiency and iron deficiency anaemia. We strive to achieve this partnership by simplifying the treatment, spearheading the improvement of patient safety, and driving the expanded use of high-dose intravenous iron across therapy fields. We also provide the first and only myeloprotective drug for patients with extensive-stage small cell lung cancer undergoing chemotherapy in the US. We are currently preparing to launch this therapy outside the US, helping even more patients with extensive-stage small cell lung cancer access innovative care.
Improved patient outcomes
We have significantly advanced the field by conducting pivotal trials and demonstrating the relative benefits of intravenous iron in large head-to-head RCTs. Our work has been instrumental in highlighting the advantages of high-dose intravenous iron, including improved patient outcomes, fewer hospitalisations and blood transfusions, enhanced healthcare utilisation, and increased patient satisfaction.
Monofer® - ferric derisomaltose 100mg/ml
Monofer is our intravenous iron for the treatment of iron deficiency and iron deficiency anaemia.
Diafer® - ferric derisomaltose 50 mg/ml
50 mg/ml solution for injection.
Cosmofer® - low Mw iron dextran
Iron dextran
IRON DEFICIENCY
Iron is essential for carrying and storing oxygen in our blood, for energy production, and for cell growth. Learn about the effects of iron deficiency on our health.
PHARMACOSMOS IS...
A global pioneer in carbohydrate chemistry and a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anaemia.
